Skip to content

Evaluation of Oral Screen Training With IQoro as Treatment for Dysphagia After Stroke

Evaluation of Oral Screen Training With IQoro as Treatment for Dysphagia After Stroke

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04868955
Enrollment
24
Registered
2021-05-03
Start date
2019-04-26
Completion date
2021-05-03
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia, Stroke

Brief summary

Purpose The purpose of the study is to evaluate if training with oral screen IQoro® improves swallowing in patients with dysphagia after stroke. Method Inpatient from a stroke unit in Sweden who have been assessed with fiberoptic endoscopic evaluation of swallowing(FEES) which proves swallowing difficulties (dysphagia) were recruited. The participants were randomise to control- or intervention group. Both groups received usual care. The intervention group were instructed to oral screen (IQoro®) training for 13 weeks. Follow up with FEES was made 13 weeks post of recruitment. The assess with FEES was recorded and the recordings are going to be analyzed afterwards to compare the swallowing ability between baseline and follow up in group and between group.

Interventions

OTHEROral screen training

Oral screen training (IQoro®) during 13 weeks.

Sponsors

Rebecca Norrman and Elin Rova
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inpatient at stroke unit at Vrinnevisjukhuset ward 1, due to stroke. * Patient assessed to have dysphagia (score ≥1 on one of the studied parameters)according to FEES. * Patient who is able to handle IQoro® according to instructions, independently or with support of assistance from relatives or staff.

Exclusion criteria

* Patients with dysphagia of a cause other than stroke. * Patient with impaired cognitive skill, motor and / or language ability that prevents the possibility of performing training with IQoro®, despite possible support from assistance from relatives or staff. * Patient who wishes training with the Muppy oral screen® related to saliva leakage.

Design outcomes

Primary

MeasureTime frameDescription
Change in swallowing function due to secretion in the pharynx.From baseline to follow up (13 weeks after baseline).Changes in swallowing function based on the parameter secretion in the pharynx. Estimates from Secretion severity rating scale, 0-3. 0= Normal rating and 3= Secretion in the laryngeal vestibule that are not cleared. Estimates are based on recording from FEES.
Change in swallowing function due to aspiration and penetration.From baseline to follow up (13 weeks after baseline).Changes in swallowing function based on the parameters aspiration and penetration in the pharynx. Estimates from Penetration aspiration scale, 0-8. 0= No entry of material into the larynx or trachea, 8= Materials enter the trachea with no attempt to clear. Estimates are based on recording from FEES.
Change in swallowing function due to residual in the pharynx.From baseline to follow up (13 weeks after baseline).Change in swallowing function due to residual in the pharynx, 0-1. 0= No or a small amount of residual, 1= A pool of residual after the first swallow. Estimates are based on recording from FEES.

Secondary

MeasureTime frameDescription
The patient's experience of swallowingFrom baseline to follow up (13 weeks after baseline)The patient estimates its own swallowing ability on the basis of a Visual analogue scale (VAS), 0-100. 0= No affected swallowing function and 100= Very affected swallowing function).
Change in swallowing function due to oral intake.From baseline to follow up (13 weeks after baseline).Change in oral intake estimates from Functional oral intake scale (FOIS), 1-7. 1= Nothing by mouth, 7= Total oral diet with no restrictions. Estimates are based on advice the patient received regarding the oral intake.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026